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Hospice management of patients receiving cytotoxic chemotherapy:
problems and opportunities
F. Hicks & G. Corcoran
St Gemma's Hospice, Moortown, Leeds LSJ7 6QD, UK.
Summary In Britain, the specialty of palliative medicine continues to develop, encouraging the referral of
patients early in the palliative phase of their illness. This has led to an increased number of patients receiving
palliative chemotherapy and hospice care concurrently, posing special problems to the professionals involved.
In this retrospective study, 52 patinets were identified who received chemotherapy and hospice care
simultaneously. Case notes were reviewed to reveal problems arising from sharing the duty of care. The poor
quality of communication between professionals, perhaps reflecting a limited understanding of the various
roles in patient care, was found to cause significant difficulties. The duration and discontinuation of cytotoxic
therapy seems to be a particularly difficult matter. Hospice admission often signalled the end of this treatment.
In a third of the patients, no decision was taken to stop chemotherapy desipite the last dose being an average
of just I week before death. The value of chemotherapy for patients who are too ill to return home is
questioned. Seven patients were diagnosed as suffering from chemotherapy-induced sepsis and neutropenia
either by hospice inpatient or home care teams, and were admitted to their acute centres accordingly. Most
patients who died during the study period received terminal care in the hospice.
Suggestions are made on improving professional education and communication, including the use of a
'chemotherapy card'.
In Britain, the specialty of palliative medicine continues to
develop, as described by Hillier (1988), encouraging the refer-
ral of patients in the palliative, rather than the terminal,
phase oftheir illness. Cancer patients are therefore being seen
by hospital-based, hospice and community palliative care
services earlier in the course of the illness than previously.
This trend, coupled with the increasing use of palliative,
cytotoxic chemotherapy by cancer physicians and surgeons,
noted by Kearsley (1986), has led to an increase in the
number of patients referred for hospice care who are concur-
rently receiving anti-cancer therapy.
Our unit began to experience difficulties in the manage-
ment of such patients. The problems appeared to fall into
three main categories: (i) Lack of detail of the patients'
current medical history. (ii) The limited education of hospice
staff in cytotoxic chemotherapy. (iii) The management of
changes to treatment philosophies, relating to the different
toxicities being acceptable depending on the phase of a
patient's illness; namely potentially curative, palliative and
terminal, Ashby and Stoffell (1991). However, the hospice
mutlidisciplinary team, concentrating on holistic care, felt
that it had much to offer in this area, West (1990). Earlier
contact with the patient and carers appeared to ease the
transitions between the curative, palliative and terminal
phases of illness. Hospice staff tended to have more time to
deal with patient and family anxieties than would be
available in a busy hospital setting, and both day care and
home support were highly valued by patients and their
carers. Timely admissions to the hospice for symptom control
or respite care appeared useful. After the administration of
chemotherapy and before the patient was able to manage at
home, the facility of intermediate care in the hospice was
often sought. Finally, staff were able to provide support
during terminal care, either for patients in their own homes
or in the hospice itself, and to continue to support families in
bereavement.
St Gemma's Hospice comprises a 45 bedded inpatient unit,
day care facilities, outpatient medical advice on pain and
symptom control, and a team of nurses providing supportive
home care in conjunction with the primary health care team.
The hospice is situated within three to five miles of the four
major referring hospitals. A system of 'shared care' is in
operation, which involves collaboration with several different
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medical, surgical and radiotherapy teams. Patients receiving
cytotoxic chemotherapy remain under the care of their hos-
pital consultants, while also receiving hospice support.
Chemotherapy is never prescribed by the hospice physicians
and decisions to initiate or stop treatment are currently made
by the hospital physician or surgeon concerned. This is a
challenge to both the hospice and hospital teams to work
together and use each others knowledge and skills to the
advantage of patients and their carers. Other hospices have
different working patterns, particularly in the organisation of
home care teams, as described by Boyd (1992).
This study was conducted in order to determine the causes
for the problems the hospice team were facing and to suggest
some solutions.
Methods
All patients admitted to St Gemma's Hospice since March
1991 have had their details entered onto a database. This
information was used to identify patients receiving cytotoxic
chemotherapy while simultaneously receiving hospice care,
during the period March 1991 to May 1992. Patients were
included in the study if they had been receiving day care,
home care or inpatient care from the hospice team either
during treatment with chemotherapy or up to 2 weeks after
the final dose. This method may have missed some patients
who received home care or day care only, since details were
not entered onto the inpatient database.
A retrospective analysis was made of the medical and
nursing case notes. Particular attention was paid to the
source of referral for hospice care, communication problems
encountered, side effects of chemotherapy, cessation of treat-
ment and eventual outcome. Referrals were made by
completing a standard form which includes a request for
information on chemotherapy regimes and dates of treat-
ment. Referrals from hospital were always made with the
permission of the consultant concerned and the GP's permis-
sion was always obtained before patients received home care.
Before transfer from hospital, all patients were assessed by a
member of the hospice team or hospital palliative care team,
where present. This provided an opportunity to discuss hos-
pice care and to ensure that patients and their carers were
happy to receive hospice involvement, as outlined by Alison
et al. (1991). In many instances, hospice admission was timed
to coincide with the end of a cycle of chemotherapy.
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Results
Over the 15 month period, 52 patients received concurrent
cytotoxic chemotherapy with a palliative intent, and hospice
care. Sixteen were male and 36 female, with a median age of
64 for men and 56 for women (range: 29-86 for either sex).
The types of diagnoses represented are illustrated in Table I.
The source of referral for hospice care and the nature of the
involvement initially requested is shown in Table II. Once the
referral had been accepted, the package of care was decided
between the hospice team and the patient and his carers, in
conjunction with the primary care team and the hospital
consultant where appropriate. Thus, a patient initially refer-
red for home care may well have spent some time in the
hospice or at day care, and vice-versa.
The main source of medical information for each patient
was the referral form. However, 24 out of 52 patients had no
mention of any chemotherapy on the form. Six of these had
been referred for hospice care before chemotherapy was in-
stituted and the medical information had not been updated.
Hospital records or photocopied notes were available on
hospice admission for 14 of the 52 patients, and susbequently
for a further ten. No notes were obtained for 28 patients. Of
18 patients transferred directly from hospital to the hospice,
only seven had an accompanying medical letter. A letter from
the GP accompanied two out of 11 patients admitted at the
GP's request. Discharge or clinic letters including updated
information on treatment and progress were sent to the
hospice for 13 of the 52 patients. On 25 occasions, patients
visited the hospital outpatient departments from their hospice
beds, with accompanying letters. Two replies were received
the same day.
Table III illustrates the range and frequency of side effects
attributed to palliative chemotherapy recorded in the hospice
case notes. For each patient, problems occurring at anytime
during chemotherapy were recorded. The actual anticancer
treatment prescribed was often not known, and this table
simply illustrates the range of problems managed by the
hospice team, without attempting to comment on the treat-
ment related toxicities of individual chemotherapeutic
regimes. Initial admission to the hospice from home was
organised either by the hospice home care team (19 patients)
or the GP (11 patients). Ten of these admissions were urgent.
Direct transfer from hospital was arranged for 22 patients as
their first hospice admission. Eighteen of these were admitted
Table I Diagnoses in patients receiving concurrent cytotoxic
chemotherapy and hospice care
Primary tumour site Number
Colorectal 9
Small cell lung cancer 7
Breast 7
Ovary 4
Non-Hodgkin's lymphoma 4
Cervix 4
Non-small cell lung cancer 3
Unknown primary 3
Sarcoma 3
Head/neck 2
Others 6
Table II Source of hospice referral and type of involvement initially
requesteda
Source of
Referral
Flospice involvement initially requested
Supportive Inpatient
home care care Total
Table III Side effects attributed to chemotherapy and number of
affected patients
Patients affected
Side effect Number Percentage
Nausea and vomiting 25 48
Bacterial infections 19 37
Severe fatigue 10 19
Candidiasis 10 19
Alopecia 10 19
Neutropenic sepsis 7 13
Mucositis 6 12
Diarrhoea 5 10
Herpes Simplex 3 6
Confusion 3 6
Neutropenia - no infection 2 4
Constipation 1 2
Premature menopause 1 2
for intermediate care after chemotherapy, and four for a
variety of other reasons.
The hospice offered the facility of 'intermediate care' for
patients who were unable to return home directly after a
cycle of chemotherapy. This type of care was requested for
patients for a variety of reasons, including chemotherapy-
related toxicity, general physical frailty, emotional care or
social difficulties. These patients were expected to return
home after 1 or 2 weeks of inpatient hospice care. Of the 18
patients transferred directly from hospital after chemo-
therapy, nine died in the hospice without returning home.
Chemotherapy was abandoned in five patients, following dis-
cussion with the consultant involved, and these patients did
return home. Four patients continued to receive cytotoxic
treatment and returned home between cycles of treatment.
In 30 of the 52 case notes, detailed discussions were
recorded with both patients and their carers on the purpose
of treatment and the value of continuing palliative chemo-
therapy in the face of difficult side effects. Seventeen patients
decided to stop treatment after discussion with hospice staff
and with the agreement of their hospital team. The consul-
tant came to the hospice to discuss these matters on three
occasions. Thirteen patients continued to receive chemo-
therapy with the full support of the hospice staff.
Overall, the first hospice admission signalled the immediate
end of cytotoxic treatment for 24 of the 52 patients. A
further 16 patients continued chemotherapy, but died in the
hospice without returning home. Twelve patients continued
chemotherapy after their first hospice discharge. On seven
occasions, patients were transferred urgently from the hos-
pice to hospital. Six of these were for the management of
acute neutropenic sepsis and one was for total dysphagia.
One patient was admitted urgently to their acute hospital by
the hospice home care team, again with neutropenia and
sepsis. Seven patients died within 72 h of hospice admission.
Blood counts to monitor the side-effects of chemotherapy
were carried out in the hospice on at least one occasion for
30 patients.
Chemotherapy was not formally stopped before death for
17 of the 52 patients, two of whom specifically requested
continued treatment. The median time elapsing between the
last dose of cytotoxic chemotherapy and death in these
patients was just 7 days (range: 2 days-6 weeks). Twelve of
these deaths were predictable after a gradual deterioration in
the patients' condition. Five were more sudden, due for
example, to intra-abdominal haemorrhage or pulmonary
embolus. Emergency transfer of these patients to hospital
was not considered appropriate and post mortems were not
performed. Thirty-four patients did stop chemotherapy,
receiving their final dose a median of 6 weeks before death
(range: 7 days-6 months). Eight of the patients who discon-
tinued treatment survive, and one continues on treatment. Of
the 52 patients in the study, 41 were known to the hospice
home care team during chemotherapy. Thirty-six ultimately
died in the hospice, five died at home, and only two in
hospital.
Hospital Palliative Care Team 13 5 18
Radiotherapy/Oncology Centre 4 9 13
General hospital, ward staff 1 4 5
General Practitioner 10 6 16
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Discussion
The 52 patients identified as receiving concurrent hospice
care and cytotoxic chemotherapy over this 15 month period,
represent a sizeable population which is likely to increase.
Although the problems of retrospective studies include the
accuracy and completeness of the records reviewed, it is
nevertheless a useful basis to observe practice before stan-
dards are set, as defined by Coles (1990). The range of
diagnoses represented reflects those commonly responding to
palliative chemotherapy, but also involves those enrolled in
clinical trials. The scope to improve the quality of care for
these patients is apparent.
Communication between professionals
From the patterns of original referral for hospice care, it can
be seen that the hospital consultant may have been unaware
of the referral in 16 of the 52 cases. Indeed, we do not know
if the hospital team considered hospice involvement to be
appropriate at that stage. In these circumstances, the GP
must be responsible for the medical information provided
and the hospice team must be sensitive to the needs of the
patient and the other professionals concerned.
The central problem identified by this study concerns the
poor communication between the different professionals
involved in patient care. While this varied between institu-
tions, nearly half of all referrals to the hospice team made no
mention of cytotoxic treatment, and more than 60% of direct
transfers to the hospice arrived without a doctors letter.
Photocopies of notes were helpful but did not always contain
the information required, necessitating a search for further
information. The reasons behind this lack of communication
are likely to be complex. Perhaps there is a lack of under-
standing in acute hospitals as to the scope of the hospices'
expertise in managing these patients. However, the transfer
of patients requiring intensive symptom management in addi-
tion to regular monitoring with blood tests, requires an
accompanying medical letter outlining (at the very least) the
drugs given and the proposed treatment plan. Ideally the
hospital notes would follow the patient, as much that the
hospice team has to offer depends on this good quality
information. For example, the side effects of treatment can
only be predicted and discussed when the actual drugs given
are known. The common question 'Will I lose my hair?'
frequently cannot be answered without this information.
Similarly, the patient's safety may depend on the knowledge
of the dates of treatment in addition to the drugs concerned.
This would help in the timing of blood tests if a patient
became more unwell. Clinic letters, arriving 2-4 weeks after
the patient had been seen, were useful in outlining treatment
strategies and protocols, but more immediate information
was necessary for hospice inpatients.
Hospice staff need to inform the hospital teams of their
involvement and to tell them of any changes of medication
that have been advised. Standards of communication are
currently being set in the hospice. At the time of this study,
telephone calls were always made to GPs on the day of a
patient's discharge or death, and hospital consultants are
now contacted in this way when a patient is known to be on
current follow up. The quality of discharge letters is being
examined. The use of problem lists, as described by Lloyd
and Barnett (1992) is being considered, and the contents of
letters are being reviewed with regard to the study by New-
ton et al. (1992), into the views of GPs and consultants on
this matter. This will form the basis for ongoing clinical
audit.
Urgent admissions
The frequency of urgent admissions, coupled with the fact
that seven patients died within 72 h of admission, highlights
once again the need for accurate, contemporary information.
The patient, family, GP and hospital consultant often need
to be consulted before urgent admission to the hospice is
arranged, as hospital admission for further investigation and
treatment may be more appropriate. Education of both
medical and nursing staff in the hospice and home care team
is being addressed, to this end. These measures should help
to improve patient safety and reduce the number of patients
requiring urgent transfer from the hospice to hospital for
more intensive treatment.
Intermediate care
The value of intermediate care in the hospice after the
administration of chemotherapy should be carefully re-
assessed in the light of the proportion of patients either dying
without going home, or ceasing cytotoxic treatment on hos-
pice transfer. If a patient is not well enough to return home
after chemotherapy, his cancer physician or surgeon needs to
ensure that he is likely to benefit from cytotoxics before
administering such treatment. From our figures, only 22%
returned home and continued chemotherapy after an admis-
sion for intermediate care. The aims of palliative chemo-
therapy must be carefully defined for all patients along the
lines described by Byrne (1992) and Rubens et al., (1992).
The paper by Rubens et al. (1992) also comments on the
many studies that have shown selected patients to benefit
from palliative chemotherapy, however, these patients in par-
ticular, may have been better served by other methods of
symptom control.
Communication with patients and carers
Hospice staff were often asked to enter into difficult discus-
sions with patients and their carers as to the value of con-
tinuing cytotoxic therapy, and education of staff in this area
is being undertaken. The complexity of the doctor-patient
relationship, particularly when discussing the relative merit of
different treatment options has been highlighted by Sensky
and Catalan (1992). They comment that anxiety and depres-
sion can occur in up to 60% of patients with serious physical
illness and may alter perceptions about their treatment. Intel-
ligent discussion with patients during the course of this study
was hampered by the lack of appropriate medical inform-
ation. Although the hospital team may feel best placed to
deal with these issues, the informal atmosphere of the hospice
or a patients home may be more conducive to such discus-
sions; moreover, a professional who is distanced from the
actual prescribing of treatment may be seen as more ap-
proachable. Many patients have loyalties to the doctors they
have known over a long period of time and may fear 'letting
them down' by questioning the value of continued treatment.
Similarly medical staff may avoid this subject in order to
'maintain hope'. Complex issues arising between family
members regarding the place of continued chemotherapy
were often confronted. Previous studies have shown that
carers often see communication with professionals as inade-
quate and would value more information, Sykes et al. (1992).
The decision to stop chemotherapy
That 33% (17/52) of patients died on chemotherapy, the last
dose being so close to death also needs addressing. Two of
these patients specifically requested that their treatment be
continued, but the other 15 had not expressed such a wish.
The continued treatment of these 15 patients, in view of the
necessary visits to hospital and blood tests, in addition to the
side effects incurred, poses many questions. In particular, the
lack of clear endpoints to some chemotherapy regimes, may
exacerbate this problem, as highlighted by Rubens et al.
(1992). Perhaps this is an area where the hospice multidiscip-
linary team should become more involved.
Education
This study has also highlighted the responsibility of hospice
staff to ensure that they have adequate knowledge of the
principles and practice of cytotoxic treatment to support1208 F. HICKS & G. CORCORAN
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Figure 1 A specimen chemotherapy treatment card.
these patients. Opportunities exist in higher specialist training
for palliative medicine, to gain experience in medical and
clinical oncology. Equally, there is an opportunity for
oncology trainees to spend some time working in a hospice.
This provides an opportunity to improve the understanding
between specialties. Hospice nursing staff are more aware of
the potential benefits of chemotherapy and the different res-
ponsibilities of looking after these patients. Certainly, during
the period of this study, as palliative care services have
become a more integrated part of patient care, the case of
joint audit between the professionals concerned has become
more apparent.
An oncology treatment card
One way of improving communication between all teams
prescribing chemotherapy, patients, primary health teams
and hospices, would be to provide a patient held record of
cancer treatment. Some centres currently use a chemotherapy
record card for this purpose, similar to that in Figure 1. The
authors are designing a more comprehensive cancer treat-
ment booklet, in conjunction with the local Department of
Medical Oncology. This will include a basic record of
radiotherapy given, in addition to chemotherapy and other
medication. It is hoped that this will undergo a pilot study
and, if successful, be put to routine use. The present study
could then be repeated, to complete the audit cycle.
Conclusions
(1) The holistic, multidisciplinary approach of hospice care
has much to offer patients receiving palliative chemotherapy
in terms ofcommunications/counselling, day care, home care,
and admissions for symptom control, respite and terminal
care. Early referral aids the continuity of care and enables
the hospice team to use its expertise, in conjunction with that
of the hospital consultant and GP, to the patients best
advantage.
(2) Education in the hospice is being addressed for all staff.
Oncological experience is usually included in higher specialist
training for palliative medicine. However, the hospice team
cannot function well in this area without accurate, contem-
porary medical information. Perhaps junior staff in oncology
should work in a hospice for a time in order to understand
these difficulties.
(3) The minimum useful information of drugs prescribed
and the dates administered could be provided on a
'chemotherapy card' given to each patient. This already
occurs in some centres and should be encouraged. It would
provide a simple, efficient way of communicating basic in-
formation, both to the specialist palliative care services and
to the patient's GP. Ideally the hospice team would also
value information on the treatment plan, assessable disease,
and protocols of current, common clinical trials, which could
be provided in a more comprehensive oncology treatment
booklet given to patients.
(4) This study indicates that joint clinical audit, coupled
with the further integration of services may help to optimise
the future management of this challenging group of patients.
The appointment of a consultant in palliative medicine and
oncology in one local teaching hospital should go some way
to achieving this.
We would like to thank Dr W.G. Jones, consultant in clinical
oncology, for his help in preparing the manuscript.
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